Track sentiment, discussions and live quotes, post ideas and see what real traders are doing

Alphabets quarterly results triggered a sharp selloff as investors focused on softer Search and advertising performance, heavy AI infrastructure spending, and negative free cash flow despite strong Cloud growth. Traders are divided between concerns that AI is disrupting Search and spending may not pay off soon, and dip buyers who see Cloud growth and the broader business as reasons the reaction is overdone.

Iovances announcement that it would present positive Phase 2 lifileucel results in previously treated metastatic lung cancer, alongside a precision-medicine update, drove attention as traders anticipated an expansion beyond melanoma. Many were enthusiastic about the potential, while others cautioned that detailed results and evidence of commercial execution still matter and that the move could meet sell-the-news pressure.

Alphabets quarterly earnings miss and heavy AI infrastructure spending, which pressured cash flow, triggered a sharp selloff and raised concerns about returns on investment and slowing search growth. Traders are divided between expecting further downside and viewing the drop as an overreaction, with bulls pointing to strong Google Cloud growth and buying the dip.

ServiceNows quarterly earnings miss and softer outlook for contracted-revenue growth triggered a sharp selloff, despite revenue growth and a raised AI target. Traders debate whether the reaction reflects valuation and slowing growth or is an overreaction to an otherwise strong quarter, while some also worry AI could pressure software companies.

Microsofts quarterly results beat expectations, led by accelerating Azure growth and strong AI-cloud demand, while capital spending came in below expectations. Traders largely welcomed the results and contrasted them with Alphabets weaker reaction, though some questioned the decline in free cash flow and whether the initial post-earnings rally would hold.

Fortinets quarterly results triggered a sharp selloff despite beating estimates and raising its full-year outlook; traders focused on slowing product growth, softer service-revenue guidance, and margin compression after a steep run-up. The community is split between viewing the drop as an overreaction to a solid report and seeing it as a valuation reset justified by weaker growth mix.

BlackRocks amended filing showing a larger 13.8% stake is being read by traders as a bullish signal, while discussion centers on the upcoming Q3 report and whether BRIUMVI sales growth and lower expenses will support results. Some expect a beat, but others are wary of a revenue miss or the stocks tendency to retreat after earnings.

Bausch Healths stronger-than-expected third-quarter results, raised outlook and share-repurchase authorization are driving attention and a sharp rally. Traders are reacting positively to the performance and debt-reduction progress, while some remain cautious about the companys substantial debt and whether the gains will hold.

Traders are focused on reported Upbit trading support changes for JASMY, with bearish posts treating them as a warning sign amid concerns about project transparency and progress. Others argue the impact is limited or overblown and are buying the dip, while the tokens broader decline adds to the debate.

Patent litigation over generic versions of Lupkynis is the main focus, with claim-construction deadlines extended and traders speculating that the delay could precede settlements; others are frustrated by the prolonged cases and limited company updates. Investors are also watching the upcoming Q3 report for evidence that Lupkynis sales growth is continuing.